A small phase I clinical trial has tested an anti-HIV strategy involving an adeno-associated viral vector-based gene delivery system that instructs cells to pump out antibodies that block HIV. In the trial of eight adults with HIV, the treatment was safe and well tolerated, and all participants produced measurable amounts of anti-HIV antibodies in the blood.